Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)

Next Previous
X
Search
Trial Profile

A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ALTISSIMO
  • Sponsors GrayBug inc.

    • Most Recent Events

    • 11 Aug 2022 According to a GrayBug inc media release, clinical trial expense decreased due to the completion of the extension phase of this trial in May 2021, this decrease was largely offset by an increase in non-clinical outside expense related to the GB-401 program and an increase in consulting fees related to the GB-501 program.
    • 03 Feb 2022 According to a GrayBug inc media release, data from this study will be presented at Angiogenesis, Exudation, and Degeneration 2022, Virtual Edition, on February 11, 2022, data will be discuss by dr. Veeral Sheth.
    • 01 Nov 2021 According to a GrayBug inc. media release, data from this study will be presented as a company's presentation at the Eyecelerator @ AAO 2021 event on November 11, 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top